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A B S T R A C T
APECED is a rare monogenic recessive disorder caused by mutations in the AIRE gene. In this manuscript, we
report a male Turkish patient with APECED syndrome who presented with chronic mucocutaneous candidiasis
associated with other autoimmune manifestations developed over the years. The presence of the homozygous
R257X mutation of the AIRE gene confirmed the diagnosis of APECED syndrome. We further performed lit-
erature review in 23 published Turkish APECED patients and noted that Finnish major mutation R257X is
common in Turks. In particular, we assessed retrospectively how often the Ferre/Lionakis criteria would have
resulted in earlier diagnosis in Finns, Sardinians and Turks in respect to the classic criteria. Since an earlier
diagnosis could have been possible in 18.8% of Turkish, in 23.8% of Sardinian and 38.55% of Finnish patients
we reviewed from literature, Ferre/Lionakis criteria could indeed allow in future earlier initiation of im-
munomodulatory treatments, if found effective in future studies.
1. Introduction
Genetically determined autoimmune/immunodysregulatory dis-
orders, more common in populations with a high rate of con-
sanguineous marriages [1,2], include the Autoimmune Polyendocrino-
pathy-Candidiasis–Ectodermal Dystrophy/Dysplasia (APECED) or
autoimmune polyendocrine syndrome type 1. This represents a rare
monogenic recessive disease caused by mutations in the autoimmune
regulator (AIRE) gene encoding for a thymus-enriched transcription
factor responsible for central immune tolerance [3]. The variability of
APECED symptoms can be partly explained by the fact that AIRE is
expressed not only in the thymus, but also in peripheral tissues, in
lymphocytes, and associated with dendritic cells differentiation and
their interaction with T cells [3]. A defect of CD4+CD25+ regulatory
T cells, key mediators of peripheral tolerance, is involved in APECED
pathogenesis due to failure of their self-antigen-driven thymic devel-
opment, maturation, peripheral activation and expansion [4,5]. Pa-
tients' sera harbor autoantibodies (Abs) to a restricted profile of tissue-
specific antigens, in contrast to what could be theoretically expected
from the extent of the AIRE-deficiency associated defect of thymic
presentation [6]. Classic diagnostic criteria for APECED was the pre-
sence of two of the following disorders: chronic mucocutaneous can-
didiasis (CMC), hypoparathyroidism (HP) and Addison's disease (AD).
Anti-interferon ω (IFN-ω) Abs are circulating at high titers. However, in
2009 diagnostic criteria were revised based on genetic and im-
munological data independently of the clinical manifestations [7].
Furthermore, 78% of the APECED patients have non-endocrine mani-
festations before the first endocrinopathy [8].
In Finnish, Sardinian and Iranian Jew populations APECED develops
at the highest described prevalences between 1:9000–1:25,000 [9] with
homozygous AIRE mutations c.769C > T, c.415C > T and c.254A >
G having a founder effect respectively [8–11]. The syndrome is de-
tected at lower incidences and with greater genetic variability
[7,9,12–23] in many European countries. American APECED patients
showed a diverse clinical picture, with dramatic enrichment of organ-
specific non-endocrine manifestations starting early in life, compared to
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Table 1
Clinical presentation, other laboratory results of the APECED patient (altered parameters are in bold).⁎
Age Clinical manifestation/therapy Autoantibodies (Abs) profile Laboratory results
from early life Oral moniliasis and onychomycosis
8-yo (admitted at Pediatric Immunology
Department, Uludag University
Chronic mucocutaneous candidiasis Candida albicans growth from swab and
tissue cultures
9-yo Watery diarrhea
Abdominal distension (autoimmune
enteropathy)
9.6-yo Sjӧgren-like syndrome with dry eyes and
mouth
10-yo Vitiligo
Alopecia
Arthralgia on knee joints (the last treated with
non-steroid anti-inflammatory drugs)
Autoimmune hemolytic anemia
Positive Abs:
RO52
RF (11.40 IU/ml)
TPH (164.3 U/ml) AADC (95.3 IU)
IFN-ω (25 IU) direct Coombs test
Anemia, otherwise
normal CBC, ferritin and fibrinogen levels
Elevated:
ESR, transaminases,
Serum Amyloid A, CRP
Negative Abs:
Borderline low serum creatinine, uric
acid, albumin and glucose
ANA
21OHAbs, 17αOH, P450scc, TGA
TPO, ICA, PCA, GBM Abs
Low IgA (other Ig classes normal)
Homozygosity for AIRE c.769C > T
(p.Arg257Ter)
ANA, anti-nuclear Abs; RO52, 52 kDa Ro/SS-A molecule; RF, rheumatoid factor; TPH, tryptophan hydroxylase; AADC, anti-aromatic L-amino-acid decarboxylase;
IFN-ω, anti-interferon omega; 21OHA, 21OH hydroxylase; 17αOH, 17 alpha OH hydroxylase; P450scc: P450 side-chain cleavage enzyme; TG, thyroglobulin; TPO,
thyroperoxidase; ICA, islet cell Abs; PCA, parietal cell Abs; GBM, glomerular basal membrane; CBC, complete blood count; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; Yo, years old.
⁎ All 14 exons and intronic regions of the AIRE gene were sequenced according to already described protocols (Genetic Analyzer 3500 Applied Biosystems
HITACHI system, ThermoFisher Scientific, Rodano (MI), Italy).
Fig. 1. Prevalence (%) of clinical manifestations in the Turkish cohort.
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European cohorts [9]. In this regard, even in highest European pre-
valence cohort, the Finns, APECED patients show an increasing and
higher recurrence of non-endocrine inflammatory manifestations, in
particular autoimmune gastrointestinal dysfunction [24]. Interestingly,
autosomal dominant AIRE mutations in the first plant homeodomain
(PHD1) zinc finger are associated with organ-specific autoimmune
conditions [25].
Epidemiological investigations thus raise questions about the va-
lidity and usability of the classic diagnostic criteria. In rare diseases, an
early diagnosis generally improves prognosis and quality of life. Unlike
in other autoimmune primary immunodeficiencies, APECED patients
generally only receive endocrine replacement therapy [26] and no
immunomodulation [27].
In this study, we report a new APECED male patient within the
Turkish population and retrospectively evaluate Turkish APECED pa-
tients in comparison to data obtained in three particular cohorts de-
rived from north (Finnish) [28] and south of Europe (Sardinian) [10],
and from both North and South America [9]. Further objective was to
verify whether the novel Ferre/Lionakis diagnostic criteria [9], which
take into consideration the appearance of non-endocrine manifesta-
tions, could improve the diagnostic efficacy in different APECED series.
Specifically, clinical diagnosis is based on development of any two-
disease components within the combined classic and adjunct triad of
urticarial eruption, intestinal dysfunction and enamel hypoplasia [9].
2. Case presentation
The patient was born (birthweight 3830 g) by caesarean section to a
26-year old mother with three previous gestations including two full-
term deliveries and one aborted fetus. Parents came from Turkey and
were unrelated. The family had no history for autoimmune diseases.
Mother's one-week-old sister and four-month-old brother had died for
unknown reasons. Patient's paternal cousin had presented with heart
and kidney anomalies and a history of frequent pneumonias.
At the age of 8 years, the patient was admitted to the Pediatric
Immunology Department of the Uludag University Medical Faculty
because of recurrent mucosal and cutaneous candidiasis since infancy.
At the age of 10 years, he developed vitiligo, alopecia, and arthralgia of
knee joints. Arthralgia was responsive to non-steroid anti-inflammatory
treatment. Concurrently, the patient had had recurrent episodes of
watery diarrhea and abdominal distension for one year and dry eyes
and mouth for six months. Ophthalmological examination was normal.
Homozygous R257X AIRE gene mutation was detected in patient's
DNA (Table 1). Abs screening revealed anti-IFN-ω specificities. Direct
positivity for anti-tryptophan hydroxylase (TPH) and anti-aromatic L-
amino-acid decarboxylase (AADC) Abs confirmed the diagnosis of
APECED and autoimmune enteropathy. Furthermore, anti-52 kDa Ro/
SS-A (RO52) antibodies associated with high rheumatoid factor titers
supported the diagnosis of Sjӧgren-like syndrome. Direct Coombs test
was positive associated with low hemoglobin values and high re-
ticulocyte count indicating autoimmune hemolytic anemia (Table 1).
3. Discussion
In this manuscript we present the clinical, immunological and ge-
netic features of a new case of APECED and review in the literature
from 2000 to date a Turkish APECED series of patients, mostly diag-
nosed on clinical findings [29–45]. Results of the analysis were com-
pared with those retrieved on Finnish, Sardinian and North/South
American cohorts [9,10,28] based on classic versus novel Ferre/
Fig. 2. Mean age of appearance of main and secondary clinical manifestations in the present Turkish APECED series. On top of each bar is reported the number of
patients (among those whose age is known) corresponding to the underlying manifestation.
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Table 2
Clinical and genetic features of 23 Turkish APECED patients including the present case report.
Turkish Patients Sex Age at referral
(years,
months)
Age of first
symptom (years,
months)
AIRE mutation Major clinical manifestations
related to APECED
Other clinical manifestations References
1 Female* 17 5 EXON 1: homozygous
p.R15H (c.44G > A)
Hypoparathyroidism Addison's
disease
CMC (esophageal candidiasis)
Autoimmune thyroiditis Ovarian
insufficiency
Autoimmune hepatitis
Hepatopulmonary
hypoxemia
(central cyanosis,
digital clubbing,
portal hypertension)
[29]
2 Male * 25 9 EXON 1: homozygous
p.R15H (c.44G > A)
Hypoparathyroidism
CMC
[29]
3 EXON 6: homozygous
p.R257X
(c.769C > T)
Hypoparathyroidism
CMC
Alopecia
Autoimmune thyroiditis
Pernicious anemia
Type 1 diabetes mellitus
[30]
4 EXON 6: heterozygous
p.R257X
(c.769C > T)
EXON 11: heterozygous
p.C457fs
(c.1370–1371 insG)
Hypoparathyroidism
Addison's disease
CMC
Nail dystrophy
Alopecia
Autoimmune hepatitis
Vitiligo
Autoimmune thyroiditis
Pernicious anemia
Keratitis
[30]
5 Male** 20 1 EXON 14: homozygous
p.P539L
INTRON 9:
11,107 G > A
Addison's disease
CMC
Hypoparathyroidism
(urolithiasis, nephrocalcinosis)
Alopecia universalis
Ectodermal dystrophy
Pernicious anemia
Vitiligo
Pneumonia
Hypergonadotropic hypogonadism
Preclinical autoimmune thyroiditis
[31]
6 Female** 17 3 EXON 14: homozygous
p.P539L
INTRON 9:
11,107 G > A
hypoparathyroidism
Addison's disease
Oral CMC
Alopecia areata
Ectodermal dystrophy
Autoimmune thyroiditis
Diabetes mellitus
Hypopituitarism (retarded growth
and pubertal development)
Non suppurative otitis
[31]
7 Female 9 8 EXON 2: homozygous
p.Tyr90-Arg92del
(C.267-275del);
C.261 G > T
homozygous
silent variation;
c.264 G > A
homozygous
silent variation
EXON 6: homozygous
c.681C > T (rs
1,055,311)
polymorphism
Oral CMC
Hypoparathyroidism
Ectodermal dysplasia
Ectodermal dystrophy of nails
Pernicious anemia
Alopecia
Atrophc gastritis
Retinal pigmentary changes
(pigment epithelial atrophy,
decreased visual acuity)
[32]
8 Male 8.11 3 EXON 6: homozygous
p.R257X
(c.769C > T)
CMC Ectodermal dystrophy
Vitiligo
Alopecia
Arthralgia
Autoimmune enteropathy
Hemolytic anemia
Undifferentiated connective tissue
disease
Preclinical Sjögren syndrome
Present
study
9 Female 33 32 not tested
(clinical diagnosis)
CMC
(candida esophagitis)
Antral gastritis
Addison's disease
Ectodermal dystrophy
Primary hypogonadism
[33]
10 Female 20 9 not tested
(clinical diagnosis)
Hypoparathyroidism
Addison's disease
Oral CMC
Ectodermal dystrophy
Suspected pericarditis
Upper respiratory infections
[34]
11 Female 18 18 not tested
(clinical diagnosis)
Hypoparathyroidism
Addison's disease
Oral CMC
Ectodermal dystrophy
Hyperpigmentation
[35]
12 Female 31 8 EXON 6: homozygous
p.R257X (c.769C > T)
Hypoparathyroidism
CMC
Vitiligo
Dental enamel hypoplasia Nail
Dystrophy
[36]
(continued on next page)
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Lionakis diagnostic criteria [10]. Our Turkish patient presented with
merely one classic clinical manifestation (CMC), and only later devel-
oped other autoimmune manifestations over the years. The presence of
the homozygous R257X mutation of the AIRE gene confirmed the
diagnosis of APECED syndrome based on the classic revised criteria [7].
Interestingly, circulating TPH, AADC and IFN-ω Abs were detected at
high titers. In this respect, the presence of cytokine Abs strongly cor-
relates with CMC according to APECED epidemiological investigations
Table 2 (continued)
Turkish Patients Sex Age at referral
(years,
months)
Age of first
symptom (years,
months)
AIRE mutation Major clinical manifestations
related to APECED
Other clinical manifestations References
13 Female 29 3 negative Hypoparathyroidism
CMC
Ectodermal dysplasia
(nail dystrophy)
Alopecia
[36]
14 not available (Autoimmune?) Adrenalitis Vitiligo
Hypothyroidism
[37]
15 Male 14 12 EXON 8: homozygous
c.964del13
Hypoparathyroidism
Addison's disease
Psoriasis vulgaris [38]
16 Male 41 41 not tested
(clinical diagnosis)
CMC
Addison's disease
Hypogonadotropic hypogonadism
(HH)
Alopecia
Vitiligo
Chronic urticaria
Chronic active hepatitis
Malabsorption
[39]
17 Male 12 12 not tested
(clinical diagnosis)
Hypoparathyroidism
Oral CMC
Amelogenesis imperfecta
Tooth eruption delay
Dental caries
[40]
18
Azerbaijan
Introns 1–4:
homozygous
IVS1-IVS4
Hypoparathyroidism
Addison's disease
CMC
Alopecia
Malabsorption
[41]
19 Female 15 15 not tested
(clinical diagnosis)
Hypoparathyroidism
Oral CMC
Epilepsy [42]
20 Female 17 17 not tested
(clinical diagnosis)
Addison's disease
Oral CMC
Hypoparathyroidism
Ectodermal dystrophy in fingernails [43]
21 Female^ 8 5 EXON 2:homozygous
p.W78R (c.232 T > C)
Hypoparathyroidism
Addison's disease
[44]
22 Female^ 4.6 4.6 EXON 2: homozygous
p.W78R (c.232 T > C)
Hypoparathyroidism [44]
23 Male 6 3 not tested
(clinical diagnosis)
Hypoparathyroidism
Addison's disease
CMC
[45]
⁎,⁎⁎, ^ siblings.
Fig. 3. Prevalence (%) of the diagnostic dyad and triad and the most common disease components of APECED in Turkish patients in comparison with the Sardinian
series published by Meloni et al. (2012) [10], the Finnish series by Perheentupa et al. (2006) [28] and the American series by Ferre et al. (2016) [9].
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[6]. Presence of TPH and AADC Abs confirmed the diagnosis of auto-
immune enteropathy in the patient. Autoantibodies against TPH and
AADC target two different enzymes important for monoamine synthesis
and present in enteric and central nervous system serotoninergic cells
[6].
This patient is part of a series of 23 Turkish APECED patients (fe-
male/male ratio: 1.71; median age at referral 17 years; range 4.6–41)
with early disease onset (median 8 years, age-range 1–41, based on the
appearance of the first component of the triad) and severe phenotype
(on average, 5.17 manifestations/patient) (Figs. 1,2). Six out of 23
patients were born from 4 consanguineous marriages out of the total 18
marriages [31,32,39,44]. The presence of another case with APECED in
the same family was reported in 3 families with a frequency of 16.6%
[29,31,44].
The penetrance of APECED is 100%, i.e. when two variant AIRE
alleles are inherited, the patient will inevitably develop the disorder.
Patient's stopgain c.769C > T (p.Arg257Ter) leads to a truncated 256
protein lacking both PHD domains, impairing its multimerization and
transactivation activity [46]. The R257X mutation was previously
identified as the Finnish major mutation, reported in 89% of Finn-
APECED chromosomes [8,47].
This was the prevalent mutation within genotyped Turkish APECED
patients since found in 30.7% (4/13) of patients in comparison to the
other genotypes, each represented in 2/13 patients. This finding con-
firms the cross-ethnicity nature of the mutation already reported in
various populations [21,48]. Of note, in the American series [9], 28.6%
of patients were homozygous for the AIRE mutation c.967_979del 13
(p.L323SfsX51), only 2.9% were homozygous for the prevalent Finnish
genotype c.769C > T while 11.4% were homozygous for wild-type
AIRE.
The analysis of the overall clinical features (Table 2) indicates the
absence of a clear phenotype/genotype correlation in Turkish APECED
patients [8–10,28]. Regarding the clinical phenotypes, the classic triad
was present in 39.1% of total patients, 87% manifested 2/3 major
manifestations. Considering patients diagnosed before the age of
30 years, of 17 Turkish APECED patients 82.4% had CMC (9/11 fe-
males, 5/6 males), while CMC was seen in 95.5% of Sardinian [10],
98% of Finnish [28] and 86% of American patients [9] (Fig. 3). Of these
17 Turkish APECED patients, 94.1% had HP (11/11 females, 5/6
males), while it was reported in 73.3% of Sardinians [10], 85% of
Finnish [28] and 91% of American patients [9] (Fig. 3). Of these series,
52.9% had AD (6/11 females and 3/6 males), while present in 68.2% of
Sardinian [10], 78% of Finnish [28] and 80% of American patients [9]
(Fig. 3).
Interestingly, several non-endocrine manifestations were reported
in the present series.
(Fig. 1) although at lower frequencies than in American APECED
cohort, where these were present in 40–80% of patients in early life.
Among non-endocrine autoimmune features, urticarial eruption, hepa-
titis, gastritis, intestinal dysfunction, pneumonitis, Sjӧgren syndrome
were represented in the Turkish patients. Indeed non-endocrine sec-
ondary diseases appeared later than the triad symptoms as opposite to
American APECED patients (Fig. 2); nevertheless, the low number of
affected patients in respect to the secondary manifestations may infer
the analysis in the present series. Interestingly, in the overall Turkish
series, HP had the earlier mean age of appearance in life than CMC,
frequently reported as first symptom [49].
Of note, we verified that the diagnostic dyad within expanded cri-
teria allowed an earlier diagnosis in 3/16 Turkish patients (18.8%) and
in 5/21 Sardinian patients (23.8%) throughout a longitudinal evalua-
tion based on the appearance of clinical characteristics until the age of
30 years (Fig. 3, Supplementary Fig. 1). Additionally, in the limited
longitudinal data related to the Finnish series published by Perheentupa
et al. [28] an earlier diagnosis could have been possible even in 5/13
Finnish APECED patients (38.55%). Data could also be retrieved by the
analysis of the Finnish series published by Merenmies and Tarkkanen
et al. [50] where, based on the appearance of chronic bilateral keratitis,
9/17 patients (52.9%) could have had an earlier diagnosis of APECED.
Thus, it is important to remember the high incidence of some non-en-
docrine manifestations such as intestinal dysfunction and ectodermal
dystrophies [24,50,51]. Clearly, as stated above, our analysis on the
Turkish series is limited by its retrospective nature since data are de-
rived from the available scientific literature on APECED. Further, in-
terpretation of results derived from the comparative applicability of the
classic versus Ferre/Lionakis criteria for an earlier APECED diagnosis
would certainly benefit from future examination of extended cohorts.
4. Conclusions
Genetic testing and counseling of APECED patients' parents and
relatives will aid in expedited diagnosis. However, APECED patients
appear nowadays to be among the most unsatisfied patient groups, with
limited success gained by the strategy of early diagnosis leading to
hormone replacement therapy alone [26,52]. Future investigations will
clarify whether the novel Ferre/Lionakis criteria [9] will indeed allow
for expedited diagnosis, and whether early-onset immunomodulatory
treatments could have the potential to avoid severe disease complica-
tions and improve patient satisfaction and/or prognosis.
Conflict of interest disclosure
None.
Funding source
This study was supported by the Italian Ministry of Health Ricerca
Corrente 201702P003967.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clim.2018.06.012.
Acknowledgments
FIRS Laboratories, RSR Ltd. (Cardiff, UK) performed Abs tests in-
cluding IFN-ω, 21OH, 17αOH, p450scc, TPH and AADC Abs.
The following are the supplementary data related to this article.
References
[1] H. Al-Mousa, B. Al-Saud, Primary immunodeficiency diseases in highly con-
sanguineous populations from Middle East and North Africa: epidemiology, diag-
nosis, and care, Front. Immunol. 8 (2017) 678, , http://dx.doi.org/10.3389/fimmu.
2017.00678.
[2] R.E. Schmidt, B. Grimbacher, T. Witte, Autoimmunity and primary im-
munodeficiency: two sides of the same coin? Nat. Rev. Rheumatol. 14 (2017) 7–18,
http://dx.doi.org/10.1038/nrrheum.2017.198.
[3] A. Fierabracci, Recent insights into the role and molecular mechanisms of the au-
toimmune regulator (AIRE) gene in autoimmunity, Autoimmun. Rev. 10 (2011)
137–143, http://dx.doi.org/10.1016/j.autrev.2010.08.019.
[4] F. Eddahri, G. Oldenhove, S. Denanglaire, J. Urbain, O. Leo, F. Andris, CD4+
CD25+ regulatory T cells control the magnitude of T-dependent humoral immune
responses to exogenous antigens, Eur. J. Immunol. 36 (2006) 855–863, http://dx.
doi.org/10.1002/eji.200535500.
[5] E. Kekäläinen, H. Tuovinen, J. Joensuu, M. Gylling, R. Franssila, N. Pöntynen,
K. Talvensaari, J. Perheentupa, A. Miettinen, T.P. Arstila, A defect of regulatory T
cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy, J. Immunol. 178 (2007) 1208–1215, http://dx.doi.org/10.4049/
jimmunol.178.2.1208.
[6] N. Landegren, D. Sharon, E. Freyhult, Å. Hallgren, D. Eriksson, P.H. Edqvist,
S. Bensing, J. Wahlberg, L.M. Nelson, J. Gustafsson, E.S. Husebye, M.S. Anderson,
M. Snyder, O. Kämpe, Proteome-wide survey of the autoimmune target repertoire in
autoimmune polyendocrine syndrome type 1, Sci. Rep. 6 (2016) 20104, , http://dx.
doi.org/10.1038/srep20104.
[7] E.S. Husebye, J. Perheentupa, R. Rautemaa, O. Kämpe, Clinical manifestations and
management of patients with autoimmune polyendocrine syndrome type I, J.
Intern. Med. 265 (2009) 514–529, http://dx.doi.org/10.1111/j.1365-2796.2009.
02090.x.
[8] P. Ahonen, S. Myllärniemi, I. Sipilä, J. Perheentupa, Clinical variation of auto-
immune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a
series of 68 patients, N. Engl. J. Med. 322 (1990) 1829–1836, http://dx.doi.org/10.
1056/NEJM199006283222601.
A. Fierabracci et al. Clinical Immunology 194 (2018) 60–66
65
[9] E.M. Ferre, S.R. Rose, S.D. Rosenzweig, P.D. Burbelo, K.R. Romito, J.E. Niemela,
L.B. Rosen, T.J. Break, W. Gu, S. Hunsberger, S.K. Browne, A.P. Hsu, S. Rampertaap,
M. Swamydas, A.L. Collar, H.H. Kong, C.R. Lee, D. Chascsa, T. Simcox, A. Pham,
A. Bondici, M. Natarajan, J. Monsale, D.E. Kleiner, M. Quezado, I. Alevizos,
N.M. Moutsopoulos, L. Yockey, C. Frein, A. Soldatos, K.R. Calvo, J. Adjemian,
M.N. Similuk, D.M. Lang, K.D. Stone, G. Uzel, J.B. Kopp, R.J. Bishop, S.M. Holland,
K.N. Olivier, T.A. Fleisher, T. Heller, K.K. Winer, M.S. Lionakis, Redefined clinical
features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy, JCI Insight 18 (2016) e88782, http://dx.doi.org/10.1172/
jci.insight.88782.
[10] A. Meloni, N. Willcox, A. Meager, M. Atzeni, A.S. Wolff, E.S. Husebye, M. Furcas,
M.C. Rosatelli, A. Cao, M. Congia, Autoimmune polyendocrine syndrome type 1: an
extensive longitudinal study in Sardinian patients, J. Clin. Endocrinol. Metab. 97
(2012) 1114–1124, http://dx.doi.org/10.1210/jc.2011-2461.
[11] J. Zlotogora, M.S. Shapiro, Polyglandular autoimmune syndrome type I among
Iranian Jews, J. Med. Genet. 29 (1992) 824–826.
[12] A.S. Wolff, M.M. Erichsen, A. Meager, N.F. Magitta, A.G. Myhre, J. Bollerslev,
K.J. Fougner, K. Lima, P.M. Knappskog, E.S. Husebye, Autoimmune polyendocrine
syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mu-
tations in the autoimmune regulator gene, J. Clin. Endocrinol. Metab. 92 (2007)
595–603, http://dx.doi.org/10.1210/jc.2006-1873.
[13] M. Dominguez, E. Crushell, T. Ilmarinen, E. McGovern, S. Collins, B. Chang,
P. Fleming, A.D. Irvine, D. Brosnahan, I. Ulmanen, N. Murphy, C. Costigan,
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in
the Irish population, J. Pediatr. Endocrinol. Metab. 19 (2006) 1343–1352.
[14] N.F. Magitta, M. Pura, A.S. Bøe Wolff, P. Vanuga, A. Meager, P.M. Knappskog,
E.S. Husebye, Autoimmune polyendocrine syndrome type I in Slovakia: relevance of
screening patients with autoimmune Addison's disease, Eur. J. Endocrinol. 158
(2008) 705–709, http://dx.doi.org/10.1530/EJE-07-0843.
[15] E.M. Orlova, A.M. Bukina, E.S. Kuznetsova, M.A. Kareva, E.U. Zakharova,
V.A. Peterkova, I.I. Dedov, Autoimmune polyglandular syndrome type 1 in Russian
patients: clinical variants and autoimmune regulator mutations, Horm. Res.
Paediatr. 73 (2010) 449–457, http://dx.doi.org/10.1159/000313585.
[16] E.M. Orlova, L.S. Sozaeva, M.A. Kareva, B.E. Oftedal, A.S.B. Wolff, L. Breivik,
E.Y. Zakharova, O.N. Ivanova, O. Kämpe, I.I. Dedov, P.M. Knappskog,
V.A. Peterkova, E.S. Husebye, Expanding the phenotypic and genotypic landscape
of autoimmune Polyendocrine syndrome type 1, J. Clin. Endocrinol. Metab. 102
(2017) 3546–3556, http://dx.doi.org/10.1210/jc.2017-00139.
[17] S.H. Pearce, T. Cheetham, H. Imrie, B. Vaidya, N.D. Barnes, R.W. Bilous, D. Carr,
K. Meeran, N.J. Shaw, C.S. Smith, A.D. Toft, G. Williams, P. Kendall-Taylor, A
common and recurrent 13-bp deletion in the autoimmune regulator gene in British
kindreds with autoimmune polyendocrinopathy type 1, Am. J. Hum. Genet. 63
(1998) 1675–1684, http://dx.doi.org/10.1086/302145.
[18] A.G. Myhre, M. Halonen, P. Eskelin, O. Ekwall, H. Hedstrand, F. Rorsman,
O. Kämpe, E.S. Husebye, Autoimmune polyendocrine syndrome type 1 (APS I) in
Norway, Clin. Endocrinol. 54 (2001) 211–217, http://dx.doi.org/10.1046/j.1365-
2265.2001.01201.x.
[19] M. Neufeld, N.K. Maclaren, R.M. Blizzard, Two types of autoimmune Addison's
disease associated with different polyglandular autoimmune (PGA) syndromes,
Medicine (Baltimore) 60 (1981) 355–362.
[20] K.T. Podkrajsek, N. Bratanic, C. Krzisnik, T. Battelino, Autoimmune regulator-1
messenger ribonucleic acid analysis in a novel intronic mutation and two additional
novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candi-
diasis-ectodermal dystrophy patients, J. Clin. Endocrinol. Metab. 90 (2005)
4930–4935, http://dx.doi.org/10.1210/jc.2005-0418.
[21] B. Stolarski, E. Pronicka, L. Korniszewski, A. Pollak, G. Kostrzewa, E. Rowińska,
P. Włodarski, A. Skórka, M. Gremida, P. Krajewski, R. Ploski, Molecular background
of polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome in a polish
population: novel AIRE mutations and an estimate of disease prevalence, Clin.
Genet. 70 (2006) 348–354, http://dx.doi.org/10.1111/j.1399-0004.2006.00690.x.
[22] M. Valenzise, A. Fierabracci, M. Cappa, P. Porcelli, R. Barcellona, F. De Luca,
S. Barollo, S. Garelli, C. Betterle, Autoimmune polyendocrinopathy-candidiasis-ec-
todermal dystrophy: report of seven additional sicilian patients and overview of the
overall series from sicily, Horm. Res. Paediatr. 82 (2014) 127–132, http://dx.doi.
org/10.1159/000363537.
[23] Ø. Bruserud, B.E. Oftedal, N. Landegren, M.M. Erichsen, E. Bratland, K. Lima,
A.P. Jørgensen, A.G. Myhre, J. Svartberg, K.J. Fougner, Å. Bakke, B.G. Nedrebø,
B. Mella, L. Breivik, M.K. Viken, P.M. Knappskog, M.C. Marthinussen, K. Løvås,
O. Kämpe, A.B. Wolff, E.S. Husebye, A longitudinal follow-up of autoimmune
Polyendocrine syndrome type 1, J. Clin. Endocrinol. Metab. 101 (2016) 2975–2983,
http://dx.doi.org/10.1210/jc.2016-1821.
[24] N. Kluger, M. Jokinen, A. Lintulahti, K. Krohn, A. Ranki, Gastrointestinal immunity
against tryptophan hydroxylase-1, aromatic L-amino-acid decarboxylase, AIE-75,
villin and Paneth cells in APECED, Clin. Immunol. 158 (2015) 212–220, http://dx.
doi.org/10.1016/j.clim.2015.03.012.
[25] B.E. Oftedal, A. Hellesen, M.M. Erichsen, E. Bratland, A. Vardi, J. Perheentupa,
E.H. Kemp, T. Fiskerstrand, M.K. Viken, A.P. Weetman, S.J. Fleishman, S. Banka,
W.G. Newman, W.A. Sewell, L.S. Sozaeva, T. Zayats, K. Haugarvoll, E.M. Orlova,
J. Haavik, S. Johansson, P.M. Knappskog, K. Løvås, A.S. Wolff, J. Abramson,
E.S. Husebye, Dominant mutations in the autoimmune regulator AIRE are asso-
ciated with common organ-specific autoimmune diseases, Immunity 42 (2015)
1185–1196, http://dx.doi.org/10.1016/j.immuni.2015.04.021.
[26] K. Kisand, P. Peterson, Autoimmune polyendocrinopathy candidiasis ectodermal
dystrophy, J. Clin. Immunol. 35 (2015) 463–478, http://dx.doi.org/10.1007/
s10875-015-0176-y.
[27] H.D. Ochs, D. Petroni, From clinical observations and molecular dissection to novel
therapeutic strategies for primary immunodeficiency disorders, Am. J. Med. Genet.
A 176 (2018) 784–803, http://dx.doi.org/10.1002/ajmg.a.38480.
[28] J. Perheentupa, Autoimmune polyendocrinopathy-candidiasis-ectodermal dys-
trophy, J. Clin. Endocrinol. Metab. 91 (2006) 2843–2850, http://dx.doi.org/10.
1210/jc.2005-2611.
[29] F. Celmeli, A. Kocabas, I.A. Isik, M. Parlak, K. Kisand, S. Ceylaner,
D. Turkkahraman, Unexplained cyanosis caused by hepatopulmonary syndrome in
a girl with APECED syndrome, J. Pediatr. Endocrinol. Metab. 30 (2017) 365–369,
http://dx.doi.org/10.1515/jpem-2016-0276.
[30] C. Mazza, F. Buzi, F. Ortolani, A. Vitali, L.D. Notarangelo, G. Weber, R. Bacchetta,
A. Soresina, V. Lougaris, N.A. Greggio, A. Taddio, S. Pasic, M. de Vroede, M. Pac,
S.S. Kilic, S. Ozden, R. Rusconi, S. Martino, D. Capalbo, M. Salerno, C. Pignata,
G. Radetti, G. Maggiore, A. Plebani, L.D. Notarangelo, R. Badolato, Clinical het-
erogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome, Clin. Immunol. 139 (2011) 6–11, http://dx.doi.
org/10.1016/j.clim.2010.12.021.
[31] T. Meyer, V. Ruppert, K. Karatolios, B. Maisch, Hereditary long QT syndrome due to
autoimmune hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome, J. Electrocardiol. 40 (2007) 504–509, http://dx.
doi.org/10.1016/j.jelectrocard.2006.12.013.
[32] H. Akil, A.D. Bulus, N. Andiran, P.S. Veber, S. Keskin, A case of autoimmune
polyendocrine syndrome type 1 with ocular findings and unique AIRE gene defect,
J. Clin. Ophthal. Res. 4 (2016) 37–39, http://dx.doi.org/10.4103/2320-3897.
174414.
[33] I. Kuzu, S.S. Zuhur, F.Y. Öztürk, S. Karatas, H.M. Özkaya, M.M. Canat, Y. Altuntas,
A case with APECED syndrome, Endocr. Abstr. 35 (2014) P221 https://doi.org/10.
1530/endoabs.35.P221.
[34] N.O. Kutbay, B.S. Yurekli, M. Yaman, M. Erdogan, S. Cetinkalp, F. Saygili, S.
Darcan, G. Ozgen, A case of polyglandular autoimmune syndrome type 1 with
hypercalcemia and hypotension, poster presented at ECE2015 Dublin, Theatr. Irel.
[35] A. Alpcan, B. Eris, S. A. Durmaz, A. Cifci, I. Kalan, A case of childhood autoimmune
polyglandular syndrome type 1, poster presented at ECE2015 Dublin, Theatr. Irel.
[36] M. Güçlü, H. Cangül, C. Ersoy, Strong, similarities in Turkish and European patients
diagnosed with APECED syndrome, Turk. J. Endocrinol. Metab. 19 (2015) 89–92,
http://dx.doi.org/10.4274/tjem.2987.
[37] H.E. Barış, A. Kıykım, E. Nain, A.O. Özen, E. Karakoç-Aydıner, S. Barış, The ple-
thora, clinical manifestations and treatment options of autoimmunity in patients
with primary immunodeficiency, Turk. Pediatri. Ars. 51 (2016) 186–192, http://dx.
doi.org/10.5152/TurkPediatriArs.2016.3928.
[38] A. Cayir, R.I. Engin, M.I. Turan, E. Pala, Psoriasis vulgaris and autoimmune poly-
endocrine syndrome type I: a case report, J. Pediatr. Endocrinol. Metab. 27 (2014)
791–793, http://dx.doi.org/10.1515/jpem-2013-0472.
[39] T. Bayraktaroğlu, H. Boztepe, S. Yarman, R. Tanakol, F. Alagöl, Geç Ortaya Çıkan
tip 1 Otoimmün Poliglandüler Yetersizlik Sendromlu Bir Olgu A case of late pre-
sented with autoimmune polyglandular syndrome type 1, Turkiye Klinikleri J. Med.
Sci. 27 (2007) 778–782.
[40] Y. Yıldırım, S. Şener, M.S. Botsalı, G. Tosun, Apeced sendromu: olgu bildirimi, Acta
Odontol. Turc. 30 (2013) 90–92.
[41] D. Cihakova, K. Trebusak, M. Heino, V. Fadeyev, A. Tiulpakov, T. Battelino, A. Tar,
Z. Halász, P. Blümel, S. Tawfik, K. Krohn, J. Lebl, P. Peterson, the MEWPE-APECED
Study Group, Novel AIRE mutations and P450 cytochrome autoantibodies in central
and eastern European patients with APECED, Hum. Mutat. 18 (2001) 225–232,
http://dx.doi.org/10.1002/humu.1178.
[42] M. Ergüven, Ü. Akyüz, Ş. Güven, F. Laloğlu, O. Bilgiç, Konvülziyon ve Karpopedal
Spazm ile Acil Servise Başvuran Tip 1 Otoimmün Poliglandüler Sendrom ve he-
liotropik Raş Birlikteliği, Zeynep Kamil Tip Bülteni 39 (2008) 203–205.
[43] D. Gökalp, S. Arikan, M. Bahçeci, A.K. Tuzcu, M. Ali Kaplan, Hipokalsemi ile
Başvuran Otoimmün Poliglanduler Sendrom (OPS) Tip 1 Olgusu, Turkiye Klinikleri
J. Endocrin. 3 (2008) 26–28.
[44] I. Esen, A. Kara, S. Ceylaner, Otoimmün Poliendokrinopati-Kandidiazis-Ektodermal
Distrofi (APECED) Sendrom'lu İki Kız Kardeş, Firat Tip Derg, Firat Med. J. 20 (2015)
225–228.
[45] B. Yuksel, N. Gokay, Tip I Poliglanduler Sendrom Olgu Sunumu, Türkiye Klinikleri
Pediatri Dergisi 9 (2000) 106–108.
[46] M. Halonen, H. Kangas, T. Rüppell, T. Ilmarinen, J. Ollila, M. Kolmer, M. Vihinen,
J. Palvimo, J. Saarela, I. Ulmanen, P. Eskelin, APECED-causing mutations in AIRE
reveal the functional domains of the protein, Hum. Mutat. 23 (2004) 245–257,
http://dx.doi.org/10.1002/humu.20003.
[47] J. Perheentupa, APS-I/APECED: the clinical disease and therapy, Endocrinol.
Metab. Clin. N. Am. 31 (2002) 295–320.
[48] M. Heino, P. Peterson, J. Kudoh, N. Shimizu, S.E. Antonarakis, H.S. Scott, K. Krohn,
APECED mutations in the autoimmune regulator (AIRE) gene, Hum. Mutat. 18
(2001) 205–211, http://dx.doi.org/10.1002/humu.1176.
[49] A. Fierabracci, Type 1 diabetes in autoimmune Polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome (APECED): a "rare" manifestation in a "rare" dis-
ease, Int. J. Mol. Sci. 17 (2016), http://dx.doi.org/10.3390/ijms17071106.
[50] L. Merenmies, A. Tarkkanen, Chronic bilateral keratitis in autoimmune poly-
endocrinopathy-candidiadis-ectodermal dystrophy (APECED). A long-term follow-
up and visual prognosis, Acta Ophthalmol. Scand. 78 (2000) 532–535.
[51] E.H. Kemp, M. Habibullah, N. Kluger, A. Ranki, H.K. Sandhu, K.J. Krohn,
A.P. Weetman, Prevalence and clinical associations of calcium-sensing receptor and
NALP5 autoantibodies in Finnish APECED patients, J. Clin. Endocrinol. Metab. 99
(2014) 1064–1071, http://dx.doi.org/10.1210/jc.2013-3723 Epub 2013 Jan 1.
[52] N. Kluger, M. Jokinen, K. Krohn, A. Ranki, What is the burden of living with au-
toimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) in
2012? A health-related quality-of-life assessment in Finnish patients, Clin.
Endocrinol. 79 (2013) 134–141.
A. Fierabracci et al. Clinical Immunology 194 (2018) 60–66
66
